Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Concluding Review Memo/E-mail for Rota CMC - Rotarix

From: Feigelstock, Dino

Sent: Wednesday, April 02, 2008 12:12 PM

To: Henchal, Laraine; Levis, Robin

Cc: Feinstone, Stephen; Krause, Philip; Vujcic, Luba; Weir, Jerry P.

Subject: concluding review memo/e-mail for Rota CMC


Upon further discussion and review of the --------------- step and the in process controls to measure product quality after ---------------, it has been concluded that GSK's use of the - --------- is appropriate and there are no remaining issues regarding this step in manufacturing.


Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 02/23/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English